Literature DB >> 33234576

MYC Activity Inference Captures Diverse Mechanisms of Aberrant MYC Pathway Activation in Human Cancers.

Evelien Schaafsma1, Yanding Zhao2, Lanjing Zhang3,4, Yong Li5, Chao Cheng6,7,8,9.   

Abstract

c-MYC (MYC) is deregulated in more than 50% of all cancers. While MYC amplification is the most common MYC-deregulating event, many other alterations can increase MYC activity. We thus systematically investigated MYC pathway activity across different tumor types. Using a logistic regression framework, we established tumor type-specific, transcriptomic-based MYC activity scores that can accurately capture MYC activity. We show that MYC activity scores reflect a variety of MYC-regulating mechanisms, including MYCL and/or MYCN amplification, MYC promoter methylation, MYC mRNA expression, lncRNA PVT1 expression, MYC mutations, and viral integrations near the MYC locus. Our MYC activity score incorporates all of these mechanisms, resulting in better prognostic predictions compared with MYC amplification status, MYC promoter methylation, and MYC mRNA expression in several cancer types. In addition, we show that tumor proliferation and immune evasion are likely contributors to this reduction in survival. Finally, we developed a MYC activity signature for liquid tumors in which MYC translocation is commonly observed, suggesting that our approach can be applied to different types of genomic alterations. In conclusion, we developed a MYC activity score that captures MYC pathway activity and is clinically relevant. IMPLICATIONS: By using cancer type-specific MYC activity profiles, we were able to assess MYC activity across many more tumor types than previously investigated. The range of different MYC-related alterations captured by our MYC activity score can be used to facilitate the application of future MYC inhibitors and aid physicians to preselect patients for targeted therapy. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33234576      PMCID: PMC7925347          DOI: 10.1158/1541-7786.MCR-20-0526

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   6.333


  73 in total

Review 1.  Reflecting on 25 years with MYC.

Authors:  Natalie Meyer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

2.  A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.

Authors:  MoonSun Jung; Amanda J Russell; Bing Liu; Joshy George; Pei Yan Liu; Tao Liu; Anna DeFazio; David D L Bowtell; André Oberthuer; Wendy B London; Jamie I Fletcher; Michelle Haber; Murray D Norris; Michelle J Henderson
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

3.  MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification.

Authors:  Mark W Zimmerman; Yu Liu; Shuning He; Adam D Durbin; Brian J Abraham; John Easton; Ying Shao; Beisi Xu; Shizhen Zhu; Xiaoling Zhang; Zhaodong Li; Nina Weichert-Leahey; Richard A Young; Jinghui Zhang; A Thomas Look
Journal:  Cancer Discov       Date:  2017-12-28       Impact factor: 39.397

4.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.

Authors:  Kerry J Savage; Nathalie A Johnson; Susana Ben-Neriah; Joseph M Connors; Laurie H Sehn; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne
Journal:  Blood       Date:  2009-08-24       Impact factor: 22.113

5.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers.

Authors:  Craig H Mermel; Steven E Schumacher; Barbara Hill; Matthew L Meyerson; Rameen Beroukhim; Gad Getz
Journal:  Genome Biol       Date:  2011-04-28       Impact factor: 13.583

6.  Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors.

Authors:  Keiichi Ohshima; Keiichi Hatakeyama; Takeshi Nagashima; Yuko Watanabe; Kaori Kanto; Yuki Doi; Tomomi Ide; Yuji Shimoda; Tomoe Tanabe; Sumiko Ohnami; Shumpei Ohnami; Masakuni Serizawa; Koji Maruyama; Yasuto Akiyama; Kenichi Urakami; Masatoshi Kusuhara; Tohru Mochizuki; Ken Yamaguchi
Journal:  Sci Rep       Date:  2017-04-04       Impact factor: 4.379

7.  High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer.

Authors:  Nidhi Gupta; Karen Jung; Chengsheng Wu; Abdulraheem Alshareef; Hind Alqahtani; Sambasivarao Damaraju; John R Mackey; Sunita Ghosh; Siham Sabri; Bassam S Abdulkarim; Gilbert Bigras; Raymond Lai
Journal:  Oncotarget       Date:  2017-04-25

8.  A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response.

Authors:  Sanjay Chandriani; Eirik Frengen; Victoria H Cowling; Sarah A Pendergrass; Charles M Perou; Michael L Whitfield; Michael D Cole
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

9.  Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression.

Authors:  Linsey Reavie; Shannon M Buckley; Evangelia Loizou; Shoichiro Takeishi; Beatriz Aranda-Orgilles; Delphine Ndiaye-Lobry; Omar Abdel-Wahab; Sherif Ibrahim; Keiichi I Nakayama; Iannis Aifantis
Journal:  Cancer Cell       Date:  2013-03-18       Impact factor: 31.743

10.  Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.

Authors:  Qingsong Gao; Wen-Wei Liang; Steven M Foltz; Gnanavel Mutharasu; Reyka G Jayasinghe; Song Cao; Wen-Wei Liao; Sheila M Reynolds; Matthew A Wyczalkowski; Lijun Yao; Lihua Yu; Sam Q Sun; Ken Chen; Alexander J Lazar; Ryan C Fields; Michael C Wendl; Brian A Van Tine; Ravi Vij; Feng Chen; Matti Nykter; Ilya Shmulevich; Li Ding
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.423

View more
  1 in total

1.  Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype.

Authors:  Andrzej Ciereszko; Mariola A Dietrich; Mariola Słowińska; Joanna Nynca; Michał Ciborowski; Monika M Kaczmarek; Kamil Myszczyński; Joanna Kiśluk; Anna Majewska; Anna Michalska-Falkowska; Natalia Kodzik; Joanna Reszeć; Ewa Sierko; Jacek Nikliński
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.